<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lee KM</submitter><funding>Ministry of Science and ICT</funding><funding>Daegu Gyeongbuk Institute of Science and Technology</funding><funding>National Research Foundation of Korea</funding><pagination>72-82</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10850280</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>48(1)</volume><pubmed_abstract>&lt;h4>Backgruound&lt;/h4>Renal fibrosis is characterized by the accumulation of extracellular matrix proteins and interstitial fibrosis. Alantolactone is known to exert anticancer, anti-inflammatory, antimicrobial and antifungal effects; however, its effects on renal fibrosis remains unknown. Here, we investigated whether alantolactone attenuates renal fibrosis in mice unilateral ureteral obstruction (UUO) and evaluated the effect of alantolactone on transforming growth factor (TGF) signaling pathway in renal cells.&lt;h4>Methods&lt;/h4>To evaluate the therapeutic effect of alantolactone, cell counting kit-8 (CCK-8) assay, histological staining, Western blot analysis, and real-time quantitative polymerase chain reaction were performed in UUO kidneys in vivo and in TGF-β-treated renal cells in vitro.&lt;</pubmed_abstract><journal>Diabetes &amp; metabolism journal</journal><pubmed_title>Alantolactone Attenuates Renal Fibrosis via Inhibition of Transforming Growth Factor β/Smad3 Signaling Pathway.</pubmed_title><pmcid>PMC10850280</pmcid><funding_grant_id>2018R1C1B6008955</funding_grant_id><funding_grant_id>2021R1A2C1011314</funding_grant_id><funding_grant_id>21-BT-06</funding_grant_id><pubmed_authors>Lee KM</pubmed_authors><pubmed_authors>Jung GS</pubmed_authors><pubmed_authors>Hwang YJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Alantolactone Attenuates Renal Fibrosis via Inhibition of Transforming Growth Factor β/Smad3 Signaling Pathway.</name><description>&lt;h4>Backgruound&lt;/h4>Renal fibrosis is characterized by the accumulation of extracellular matrix proteins and interstitial fibrosis. Alantolactone is known to exert anticancer, anti-inflammatory, antimicrobial and antifungal effects; however, its effects on renal fibrosis remains unknown. Here, we investigated whether alantolactone attenuates renal fibrosis in mice unilateral ureteral obstruction (UUO) and evaluated the effect of alantolactone on transforming growth factor (TGF) signaling pathway in renal cells.&lt;h4>Methods&lt;/h4>To evaluate the therapeutic effect of alantolactone, cell counting kit-8 (CCK-8) assay, histological staining, Western blot analysis, and real-time quantitative polymerase chain reaction were performed in UUO kidneys in vivo and in TGF-β-treated renal cells in vitro.&lt;</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2026-07-15T02:40:38.848Z</modification><creation>2025-04-04T10:40:13.396Z</creation></dates><accession>S-EPMC10850280</accession><cross_references><pubmed>38173367</pubmed><doi>10.4093/dmj.2022.0231</doi></cross_references></HashMap>